Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18331573 | 0.77 | NOTUM (0.40) | ADORA2AADORA3ADORA2BADORA1NOTUM | |
| SCHEMBL11185171 | 0.77 | NOTUM (0.40) | ADORA2AADORA3ADORA2BADORA1NOTUM | |
| SCHEMBL10645494 | 0.74 | ALDH1A1 (0.50) | NOTUMALDH1A1KDM4EMEN1LMNA | |
| SCHEMBL18327510 | 0.73 | NOTUM (0.37) | ADORA2ANOTUMALDH1A1KDM4EMEN1 | |
| SCHEMBL20016416 | 0.73 | SLC5A2 (0.41) | ADORA2ANOTUMALDH1A1KDM4EMEN1 | |
| SCHEMBL17065282 | 0.73 | LMNA (0.46) | ALDH1A1KDM4EMEN1LMNAGAA | |
| SCHEMBL4204419 | 0.70 | POLB (0.40) | NOTUMALDH1A1KDM4EMEN1LMNA | |
| SCHEMBL12402363 | 0.69 | ALDH1A1 (0.41) | ADORA2AADORA3ADORA2BADORA1NOTUM | |
| SCHEMBL2274010 | 0.69 | CA12 (0.41) | MEN1KMT2A | |
| SCHEMBL2156717 | 0.69 | KDM4E (0.41) | KDM4EMEN1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388536-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2025-12-25 | — | — | US | disclosed |
| CN-118871422-A | 3-Alkynyl carboxamides as AEP modulators | 豪夫迈·罗氏有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023165943-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| US-7514567-B2 | Oxazolidinone nicotinic acetylcholine receptor agonists | ASTRAZENECA AB (SE) | 2009-04-07 | — | — | US | disclosed |
| CN-1829721-A | Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor | ASTRAZENECA AB (SE) | 2006-09-06 | — | — | CN | disclosed |
| US-20060154945-A1 | Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | US | disclosed |
| EP-1654264-A1 | SPIRO [1-AZABICYCLO [2.2.2]OCTANE-3,5'-OXAZOLIDIN-2'-ONE] DERIVATIVES WITH AFFINITY TO THE ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR | AstraZeneca AB (SE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005005435-A1 | SPIRO ′1-AZABICYCLO ′2.2.2!OCTAN-3,5′-OXAZOLIDIN -2′-ONE! DERIVATIVES WITH AFFINITY TO THE ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388536-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | CNR2, CNR1, FAAH2 | ADORA2A 885/4885ADORA3 786/4885ADORA2B 509/4885 |
| US-20060154945-A1 | Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor | CHRNA1, CHRNA7, ADRA1D | ADORA2A 36/4885ADORA3 44/4885ADORA2B 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.